Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
List view / Grid view
Myelodysplastic syndromes (MDS)
Researchers have uncovered how mutations affecting RNA splicing alter cells to develop myelodysplastic syndrome (MDS).
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
24 March 2016 | By Victoria White
Apogenix’s APG101 rescues the production of red blood cells (erythropoiesis) in bone marrow samples from patients with lower-risk myelodysplastic syndromes...